These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8703944)

  • 1. Topological folding and proteolysis profile of P-glycoprotein in membranes of multidrug-resistant cells: implications for the drug-transport mechanism.
    Zhang M; Wang G; Shapiro A; Zhang JT
    Biochemistry; 1996 Jul; 35(30):9728-36. PubMed ID: 8703944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural flexibility of the linker region of human P-glycoprotein permits ATP hydrolysis and drug transport.
    Hrycyna CA; Airan LE; Germann UA; Ambudkar SV; Pastan I; Gottesman MM
    Biochemistry; 1998 Sep; 37(39):13660-73. PubMed ID: 9753453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport.
    Eckford PD; Sharom FJ
    Biochemistry; 2008 Dec; 47(51):13686-98. PubMed ID: 19049391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue distribution of the human MDR3 P-glycoprotein.
    Smit JJ; Schinkel AH; Mol CA; Majoor D; Mooi WJ; Jongsma AP; Lincke CR; Borst P
    Lab Invest; 1994 Nov; 71(5):638-49. PubMed ID: 7734012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains.
    Liu R; Sharom FJ
    Biochemistry; 1996 Sep; 35(36):11865-73. PubMed ID: 8794769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells.
    Chen Y; Pant AC; Simon SM
    Cancer Res; 2001 Nov; 61(21):7763-9. PubMed ID: 11691790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen.
    Lee JS; Paull K; Alvarez M; Hose C; Monks A; Grever M; Fojo AT; Bates SE
    Mol Pharmacol; 1994 Oct; 46(4):627-38. PubMed ID: 7969041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism involved in generating the carboxyl-terminal half topology of P-glycoprotein.
    Han ES; Zhang JT
    Biochemistry; 1998 Aug; 37(34):11996-2004. PubMed ID: 9718325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-cycle-dependent turnover of P-glycoprotein in multidrug-resistant cells.
    Zhang W; Ling V
    J Cell Physiol; 2000 Jul; 184(1):17-26. PubMed ID: 10825230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane orientation of carboxyl-terminal half P-glycoprotein: topogenesis of transmembrane segments.
    Han ES; Zhang JT
    Eur J Cell Biol; 1999 Sep; 78(9):624-31. PubMed ID: 10535304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
    Regev R; Katzir H; Yeheskely-Hayon D; Eytan GD
    FEBS J; 2007 Dec; 274(23):6204-14. PubMed ID: 17986257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of random recombination between human MDR1 and mouse mdr1a cDNA in a pHaMDR-dihydrofolate reductase bicistronic expression system.
    Shoshani T; Zhang S; Dey S; Pastan I; Gottesman MM
    Mol Pharmacol; 1998 Oct; 54(4):623-30. PubMed ID: 9765504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voacamine, an alkaloid extracted from Peschiera fuchsiaefolia, inhibits P-glycoprotein action in multidrug-resistant tumor cells.
    Meschini S; Marra M; Condello M; Calcabrini A; Federici E; Dupuis ML; Cianfriglia M; Arancia G
    Int J Oncol; 2005 Dec; 27(6):1597-603. PubMed ID: 16273216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells.
    Ghetie MA; Ghetie V; Vitetta ES
    Clin Cancer Res; 1999 Dec; 5(12):3920-7. PubMed ID: 10632321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1).
    Ambudkar SV; Kim IW; Sauna ZE
    Eur J Pharm Sci; 2006 Apr; 27(5):392-400. PubMed ID: 16352426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proximity of the nucleotide binding domains of the P-glycoprotein multidrug transporter to the membrane surface: a resonance energy transfer study.
    Liu R; Sharom FJ
    Biochemistry; 1998 May; 37(18):6503-12. PubMed ID: 9572868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulator-induced interference in functional cross talk between the substrate and the ATP sites of human P-glycoprotein.
    Maki N; Moitra K; Silver C; Ghosh P; Chattopadhyay A; Dey S
    Biochemistry; 2006 Feb; 45(8):2739-51. PubMed ID: 16489767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transmembrane aromatic amino acid distribution in P-glycoprotein. A functional role in broad substrate specificity.
    Pawagi AB; Wang J; Silverman M; Reithmeier RA; Deber CM
    J Mol Biol; 1994 Jan; 235(2):554-64. PubMed ID: 7904655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catalytic mechanism of P-glycoprotein.
    Senior AE
    Acta Physiol Scand Suppl; 1998 Aug; 643():213-8. PubMed ID: 9789563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein.
    Kang CD; Ahn BK; Jeong CS; Kim KW; Lee HJ; Yoo SD; Chung BS; Kim SH
    Exp Cell Res; 2000 Apr; 256(1):300-7. PubMed ID: 10739677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.